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1.  Introduction 
From time to time a major global research publication appears which has profound implications for 
the pain research and clinical management community. The purpose of this article is to draw to the 
attention of PAIN’s readership one such article, The Global Burden of Disease (GBD) Study 2013 
which was recently published in the Lancet [26]. It comprises a comprehensive and extensive 
assessment of the global burden of disease down to country level. The GBD Study also documents 
changes in this burden over a 23 year period ending in 2013. Looking forward, there are plans for 
these data to be updated on an annual basis.   
Here, we summarise, interpret and contextualise the key aspects of the GBD Study 2013 pertaining 
to pain. What is striking, and indeed highlighted in an accompanying commentary [4], about the 
morbidity and disability burden data is the high prominence of pain, and diseases associated with 
pain, as a global cause of disability in both the developed and developing world. Furthermore, an 
important implication is that whilst some diseases have decreased in prevalence since 1990 (most 
notably some associated with acute infectious diseases), those burdens associated with chronic pain 
are in many cases increasing. This is at least partly because of powerful demographic forces such as 
the aging of populations in the developed world and similarly increased survival into middle and old 
age in the developing world, resulting both in growing population size and rising prevalence of 
chronic diseases. In GBD 2010 40% of the overall disease burden in developing countries was due to 
communicable diseases, 49% to non-communicable diseases (NCDs), and 11% to injuries, and the 
poorest people in the world were affected at younger ages (40 and under) [27]. In developing 
countries populations are ageing at a much faster rate than occurred in developed countries: in the 
UK it took 45 years for the proportion of the population aged over 65 to double from 7% to 14% 
while it is predicted to take only 14 years in Columbia. To quote Alex Kalache [14] “The developed 
world became rich before it became old. In developing countries, people are becoming old before 
they become rich”.  
2.  What did they measure, and how? 
The GBD Study 2013 was a major project [26], the paper having 679 co-authors, 58 pages and 1,868 
pages of online appendix.  Data on 301 diseases and injuries, and 2,337 of their sequelae were 
drawn from 188 countries, providing systematic evidence on disease burden at global, regional and 
national levels.   
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For acute conditions (<3 months’ duration), the incidence was presented (number of new cases in 
2013 per 100,000 population); for chronic conditions, prevalence was presented (total number of 
individuals with the condition in 2013, and the number of individuals per 100,000 population).  In 
addition, the impact of the diseases and their sequelae was calculated as ‘Years Lived with Disability’ 
(YLDs) – the prevalence multiplied by a rigorously derived disability weighting factor that represents 
the public’s assessment of the severity of health loss.   
The methods are clearly described in the paper and were developed from those used in the 2010 
GBD study [27], and results were compared with the re-analysed results of the first GBD study, 
which was in 1990.   
 
3.  The global burden of disease – a painful picture 
The GBD Study showed that only a small fraction of the world’s population (4.3%) was free of 
disease, injury or sequelae.  Because of increases in world population and life expectancy, the total 
number of individuals suffering almost every condition increased, and the prevalence of multi-
morbidity also increased.  Furthermore, mortality was found to be declining faster than disease 
prevalence and disability, with a resultant growth in the overall burden of disease. In other words, 
while life expectancy has increased, healthy life expectancy has not kept pace. 
The commonest acute conditions, by far, were upper respiratory infections with in excess of 18.7 
billion cases in 2013, increased by 38% in number since 1990, and 6.5% in age-standardised rate.  
Most of the commonest acute conditions were infectious diseases and short-term injuries, but tooth 
pain due to permanent caries was the 5th commonest acute condition, with more than 200 million 
cases estimated in 2013 (an absolute increase of 36% since 1990, and a rate increase of 1.4%). 
A total of 59 chronic conditions were estimated each to have a global prevalence in excess of 1%, 
with eight conditions affecting more than 10% of the global population.  The commonest of these 
was asymptomatic dental caries (2.4 billion individuals, rising from 1.7 billion in 1990).  Second 
commonest (and therefore the commonest symptomatic chronic condition) was recurrent tension-
type headaches (1.6 billion in 2013, up from 1.1 billion in 1990); the age-standardised rate of this 
condition was unchanged in the comparison period.  Seven of the commonest chronic conditions 
were found to be primary pain conditions – migraines were the 7th commonest, low back pain was 
12th, neck pain was 19th, ‘other musculoskeletal conditions’ were 32nd, osteoarthritis 33rd, and 
urolithiasis was 57th.  Although these all demonstrated large increases in total numbers of individuals 
affected, the age-standardised rates of chronic conditions were mostly either unchanged or only 
slightly reduced in comparison with 1990.  Only five conditions demonstrated an increase in rate, 
including ‘other musculoskeletal conditions’, for which a 6.6% increase in rate was estimated, and 
urolithiasis (20.1% increase). 
Probably, though, the most important picture of disease burden is represented by the YLDs, which 
take both the prevalence and severity into account.  YLDs describe the impact of conditions on 
individuals, and by implication on their communities and societies, and the health and social services 
which must provide for them.  Many of the most prevalent conditions (e.g.  asymptomatic dental 
caries) are found to contribute less to YLDs, because of relatively low disability weightings.  It is 
therefore in examining causes and rates of YLDs around the world that we find chronic pain to be 
the most important condition – globally, regionally, and in every individual country. It should be 
noted that for some regions (especially developing country areas such as Sub-Saharan Africa) there 
were no or scant primary data and the YLDs were estimated from the population structure and 
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weighted prevalence rates from other regions. There is still a great need for primary data from these 
areas to improve burden estimation. 
Globally, the single greatest cause of YLDs was chronic low back pain, which was estimated to cause  
more than 146 million YLDs in 2013, an increase of 61% since 1990 (with no significant change in 
age-standardised rate).  This compares with the second greatest cause – major depressive disorder – 
which contributed in excess of 51 million YLDs (increased in number by 53% since 1990, and in rate 
by 4.7%).  Chronic neck pain was the 4th greatest cause (>34 million YLDs); migraine was 6th (>28 
million YLDs); ‘other musculoskeletal disorders’ was 10th (>22 million YLDs); osteoarthritis was 13th 
(>12 million YLDs); and medication overuse headache was 18th (>9 million YLDs).  The main four 
chronic pain conditions featured in the top ten causes of YLDs both in developed countries and in 
developing countries. 
Indeed, chronic back pain and chronic neck pain featured in the top ten causes of YLDs in every 
country examined, and migraine was also ranked in the top ten everywhere other than Sub-Saharan 
Africa. Musculoskeletal disorders together with fractures and soft tissue injuries accounted for 
20.8% of all YLDs globally in 2013.  Mental health conditions were also important causes of YLD, with 
major depressive disorder appearing in every country’s list of top ten causes, and anxiety featuring 
prominently; both of these are important co-morbidities with chronic pain.  Regions with notable 
variation from the most important global causes of YLDs were Africa and the Middle East.  In North 
Africa and the Middle East, opioid use disorder was listed as the 8th most important cause (and the 
most important in Qatar). Data for every country and condition assessed are available as 
supplementary tables in the paper’s extensive online appendix. 
The study was designed to assess the global burden of disease, and cannot provide definitive 
explanations for the findings.  However, the authors postulate that the main reasons for the increase 
in YLDs caused by these chronic pain conditions are related to ageing populations (rates of YLDs are 
declining much more slowly than mortality rates), increasing obesity and reducing levels of physical 
activity. Rates of obesity, road traffic accidents, other types of injury are all increasing in the 
developing world. They further note that there is still little policy discussion around their prevention 
and management, despite their burden being highlighted as larger than expected in the GBD 2010 
Study [27].  
 
4.  The burden of “hidden” pain 
The preceding section documents how chronic pain is clearly the most important current and future 
cause of morbidity and disability across the world, with large recent increases in both the number of 
individuals affected and years lost to disability, coupled with static or rising prevalence rates.  
However, even this picture actually under-estimates the total burden imposed by chronic pain.  Here 
we discuss a number of disparate exemplar conditions where pain can be a major feature, although 
it was not possible to ascertain the exact contribution of pain to the overall YLD from the published 
GBD data. 
The diabetes pandemic is well documented and diabetes was ranked as the 7th most important 
cause of YLDs globally, rising from 10th in the 1990 survey – a percentage change of 136% and now 
accounting for 29 .5 million YLD. Up to 26% of type 2 diabetics suffer from painful diabetic 
neuropathy, representing a population prevalence of 0.8% [25]. 
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With respect to infectious diseases, in Sub-Saharan Africa, diseases arising from HIV/AIDS (other 
than mycobacterial infection) were listed as the 4th most important cause of YLDs, and were top of 
the list in six countries. The number of YLDs caused by HIV-related diseases, standing at >4 million in 
2013, had increased by more than 300%, with an age-standardised rate increase of 172% since 1990. 
HIV/AIDS is associated with many causes of pain, but one of the most relevant, especially as the 
trend towards to world-wide access to antiretroviral drugs continues, is HIV-associated sensory 
neuropathy (HIV-SN). The anticipated decline in HIV-SN with withdrawal of neurotoxic antiretroviral 
drugs is not yet evident and this peripheral neuropathy still afflicts between 27% and 57% of people 
living with HIV of whom between 38% and 90% experience neuropathic pain [8; 11; 21]. Therefore, 
HIV-SN is one of the most frequent manifestations of HIV in people who are adequately treated with 
antiretroviral drugs.  The burden of neuropathic pain in HIV-SN is further increased as it is peculiarly 
resistant to analgesic therapies which are effective in other painful neuropathies [9; 12; 22; 23].  
Varicella and herpes zoster were globally associated with 198,000 YLDs, having increased by 48% 
since 1990, although there was a slight decline when the age-standardised change was taken into 
account. However, it is not possible to ascertain to what extent this is attributable to the main 
chronic pain complication of zoster, postherpetic neuralgia. Whilst postherpetic neuralgia would be 
expected to become more prevalent with an ageing population, this may well be mitigated by the 
ongoing introduction of zoster vaccination in a number of countries [20].  
Although now a comparably rare disease globally, leprosy is still prevalent in parts of the developing 
world and accounted for some 40,000 YLDs, these having increased by 73% since 1990 (age 
standardised increase 6%). Some of this burden is probably attributable to neuropathic pain, which 
chronically afflicts some 20-25% of leprosy patients even long after mycobacteriological cure, 
because of persisting nerve damage and new immune mediated neuritis reactions [13; 18; 24]. 
Overall cancer accounted for 6.8 million YLDs, an increase of 83% (age adjusted 8.5 million YLDs).  
Neuropathic or mixed pain has been found to affect 20-40% of people with cancer [5]. These findings 
are importantly contextualised by considering ongoing gains in cancer survival for many common 
cancers. 
We are increasingly aware of the importance of neuropathic pain in neurological disorders and it is 
notable, for example, that multiple sclerosis and Parkinson’s disease accounted for 755,000 and 
695,000 YLDs respectively, both having increased since 1990.  
Sickle cell disorders and trait accounted for 342,000 and 1.4 million YLDs respectively.  
Disability following war and conflict were ranked as the top causes of YLDs in Cambodia, Nicaragua, 
and Rwanda and second in Vietnam. Modern munitions dictated that limb trauma and amputation 
(and therefore post amputation pain) were one of the major survivable injuries of the First World 
War [10] and this continues to be a major feature of modern day conflicts, including those inflicted 
on civilians by landmines long after active conflicts have finished  [3; 7; 16; 17; 19].   
Finally, the contribution of harms associated with analgesic treatments to the global burden of 
disease cannot be ignored, although it is difficult to ascertain the exact impact of prescribed, as 
opposed to misused, therapies. Overall the adverse effects of medical treatment globally accounted 
for 201,000 YLDs. Nevertheless, it is sobering to note in passing that opioid use disorders accounted 
for 5.8 million YLDs and medication overuse headache for 9.8 million, with both having risen since 
1990. Cannabis is often advocated for the treatment of pain, particularly neuropathic pain, despite a 
distinct lack of evidence for efficacy and unknown risks of harm [12] – cannabis use disorders 
accounted for 396,000 YLDs.  
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5. Implications for pain research, practice and policy. 
GBD 2010 [27] and 2013 [26] changed our understanding of the huge global burden of disease that is 
driven by pain conditions, and also highlighted areas where the pain community can contribute to 
further improvements in how this burden is accurately assessed and, ultimately, reduced. This global 
challenge requires an agenda and action plan that must span research, policy and practice, and 
actively address the problems pertaining both to developed and to developing countries.  
The over-arching priority is global recognition of chronic pain as a distinct clinical entity, rather than 
merely as a symptom of other conditions, with funding specifically identified and allocated to 
address this most disabling of conditions across a diverse range of diseases and settings.  
5.1 Research 
Pain research has historically been – and continues to be - a low priority for research funders; for 
example in 2007 only 0.61% of the United States National Institutes of Health budget was allocated 
to pain research [1]. Funding for clinical services has been similarly problematic. 
Experience to date with estimating the global burden of pain has identified significant gaps in our 
basic understanding of how pain affects populations, ranging from the prevalence of common pain 
conditions to the cultural dimensions of pain burden (such as stigma and shame) in different 
societies.  
We need population studies that measure burden of pain (occurrence and impact) in countries 
where no primary studies have been done, most notably in developing countries and regions such as 
Sub-Saharan Africa. This will first require the development of standardised and robust measures for 
use in population studies of common pain-associated conditions such as neck pain.  Then we need 
better characterisation of the natural history and main trajectories of common pain conditions so 
that incidence and remission rates, as well as prevalence rates and the proportions who experience 
pain-related disability at all levels of severity, can be better understood. There is a need for better 
measurement of neuropathic and disease-associated pain, and a more consistent approach to 
characterising pain as a sequel of injury (for example, spinal cord injury), surgery or disease.  
New population-level studies are also needed to assess how the cross-cutting risk factors for chronic 
diseases – such as poverty, diet, obesity, physical activity levels and other common exposures 
associated with chronic diseases – interplay with pain within an explicit public health framework [6]. 
Linked to this will be the identification and implementation of policy and political approaches to 
reducing the burden of chronic pain.  These are at least as important as clinical interventions, given 
the association of chronic pain with poverty and secular demographic trends in the societies 
affected. 
5.2 Practice 
A number of areas of clinical practice require scrutiny in the light of the high visibility of pain in the 
GBD picture. However, those of us involved in clinical pain management should also recognise that 
our efforts are likely to be more effective if they are conducted not in isolation, but rather imbedded 
as part of an overall multi-disciplinary rehabilitation programme aimed at returning individuals to 
functioning as productive members of their societies.  
To directly address the burden of disease, research must continue to identify and evaluate new 
clinical interventions for chronic pain, including its prevention.  These will include a range of 
modalities and/or be multi-modal, including pharmacological, physical, psychological, social and 
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surgical. Nevertheless, for effective translation of new and existing evidence on prevention and 
treatment into clinical practice it is arguably time for the international pain community to become 
more active in adopting emerging key factors in successful translation and implementation from the 
rapidly developing field of implementation science.  
However, changing practice is not just about introduction of novel interventions, but also, 
importantly, implementation of existing evidence-based effective, and cost-effective, treatments for 
chronic pain throughout community, primary care and specialist care settings (see for example: 
Scottish Intercollegiate Guideline Network guidelines (SIGN) [2]. These include many interventions 
that are relatively inexpensive (e.g. self-management; physical activity) and that are suitable for 
delivery to large numbers of people in low resource settings. Associated with this is the development 
of “minimum” and “optimum” standards of pain service provision appropriate to each country, 
including staffing levels and increased local availability of appropriate drugs on the WHO Essential 
Medicines Lists [15].  International review and comparisons of current service provision in 
comparison with such standards will be essential, as will strategies to bridge the gaps. 
Finally, as ever, appropriate education of healthcare professionals and managers, patients, and 
society in the mechanisms, prevention and management of chronic pain is vital. 
5.3. Implications for policy  
We need to articulate a coherent and integrated framework for pain conditions, to be used within 
the GBD and other policy contexts.  This should to replace the somewhat fragmented and 
conceptually clouded approach to date in which some, but not all, common regional pain conditions 
are included, where pain is not explicitly included as an important sequel of other conditions, and 
the role of pain as a risk factor for other conditions is not well-conceptualised. Despite the current 
approach, enough is known about the global pain burden to warrant significant responses from 
global and national agencies. The WHO’s focus on non-communicable diseases remains on 
cardiovascular and respiratory diseases, diabetes and cancer. This is noteworthy, as there is little to 
suggest to date that there has been significant institutional response to the GBD evidence about 
pain burden.  It is incumbent on the pain community to engage with the ongoing GBD initiative, and 
to advocate globally, for action and progress on the universal burden of pain.  
The difficulties of undertaking research and interventions in resource-poor countries are substantial 
and are likely to require active engagement with the WHO, the United Nations, and potentially 
partnering with other professional associations. For example the Bone and Joint Decade 
(www.bjd.org.au) notably played a key role in supporting the work of the expert reference group for 
musculoskeletal conditions in GBD 2010.  Much of this research is likely to be done by researchers 
whose primary expertise is not in pain research (for example, studies where pain is the sequel of 
other conditions), again pointing to the importance of collaborations and partnerships. Another 
form of engagement would be for members of the international pain community with the relevant 
expertise to have direct input through the GBD collaborators network (www.healthdata.org/gbd). 
In conclusion, GBD 2013 [26] has changed our understanding of the huge burden of disease and 
disability that is driven by pain-associated conditions and places chronic pain firmly at the crux of 
healthcare provision - this has major societal implications for research, planning, delivery and 
resource allocation. Looking forward and empowered by this knowledge, it is incumbent on the 
global pain research and clinical communities to recognise and address this challenge, interact with 
and influence the GBD programme and its methods, and advocate for a better and more detailed 
understanding of pain as the major component of global disease burden.  Carpe diem! 
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